Intra-Cellular Therapies Inc (NASDAQ:ITCI)
| 42.61 Delayed Data As of 4:00pm ET |  +3.71 / +9.54%Today’s Change | 28.40 Today|||52-Week Range 55.20 | -18.59% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $4.0B |
Company Description
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
Contact Information
Intra-Cellular Therapies, Inc. 430 East 29th Street New York New York 10016 |
Employees
Shareholders
| Mutual fund holders | 52.46% |
| Other institutional | 32.43% |
| Individual stakeholders | 15.40% |
Top Executives
| Sharon Mates | Chairman, President & Chief Executive Officer |
| Lawrence J. Hineline | Chief Financial Officer, Treasurer & SVP-Finance |
| Robert E. Davis | Chief Scientific Officer & Senior Vice President |
| Suresh Durgam | Chief Medical Officer & Senior Vice President |
| Karen Patruno Sheehy | Chief Compliance Officer & Senior Vice President |
